The drug industry and medical practice - The case of menopausal hormone therapy in Estonia

Social Science and Medicine

Volumn 58, Issue 1, 2004, Pages 89-97

  Hemminki, Elina ^a   Karttunen, Tiina ^a   Hovi, Sirpa Liisa ^a   Karro, Helle ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF TARTU   (Estonia)

Author keywords

Drug advertising; Estonia; Hormone therapy; Menopause; Physicians; Prescribing

Indexed keywords

HORMONE;

DRUG PRESCRIBING;

ADULT; AGED; ARTICLE; CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INDUSTRY; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; DRUG USE; ESTONIA; FEMALE; FINLAND; GENERAL PRACTITIONER; GYNECOLOGY; HEALTH CARE; HEALTH EDUCATION; HORMONAL THERAPY; HUMAN; INFORMATION PROCESSING; MALE; MEDICAL LITERATURE; MEDICAL PRACTICE; MENOPAUSE; PHYSICIAN ATTITUDE; POPULATION RESEARCH; PRESCRIPTION; QUESTIONNAIRE; RANDOMIZATION;

EID: 0142248913     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0277-9536(03)00150-3     Document Type: Article

References (29)

1. Andersson G., Lexchin J. Strategies for improving prescribing practice. Canadian Medical Association Journal. 54:1996;1013-1017.
2. Anonymous (1995). Interview. European Menopause Journal 2, Number 1: I-III; Number; 4: I-IV.
3. Anonymous (1996). Interview. European Menopause Journal 3, Number 2: I-II; Number 4: I-III.
4. Avorn J., Chen M., Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. The American Journal of Medicine. 73:1982;4-8.
5. Barret-Connor E. Hormone replacement therapy. British Medical Journal. 317:1998;457-461.
6. Burns H. Disease management and the drug industry. Care out or carve up? Lancet. 347:1996;1021-1023.
7. Choudhry N.K., Stelfox H.T., Detsky A.S. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. Journal of the American Medical Association. 287:2002;612-617.
8. Davis D., Thomson M., Oxman A., Haynes R. Changing physician performance. A systematic review of the effect of continuing medical education strategies Journal of the American Medical Association. 274:1995;700-705.
9. Estonian State Agency of Medicine. Available http://www.sam.ee/index.aw? section=88, (accessed: 11.3.2002).
10. Haajer-Ruskamp, F., & Hemminki, E., (1993). The social aspects of drug use. In: M.N.G. Dukes (Ed.), Drug utilization studies - methods and uses (pp. 97-124). WHO Regional Publications, European series, No 45. Copenhagen: World Health Organization.
11. Hemminki E., Topo P., Malin M., Kangas I. Physicians' views on hormone therapy around and after menopause. Maturitas. 16:1993;163-173.
12. Hemminki E. Factors influencing prescribing. Ghodse A., Khan I. Psychoactive drugs: improving prescribing practices. 1998;22-32 World Health Organization, Geneve.
13. Hemminki E., Sihvo S. A review of post-menopausal hormone therapy recommendations. Potential for selection bias Obstetrics and Gynecology. 82:1993;1021-1028.
14. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., Vittinghoff, E., for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association, 280, 605-613.
15. Kiivet R., Bergman U., Rootslane L., Rägo L., Sjögvist F. Drug use in Estonia in 1994-1995. A follow-up from 1989 and comparison with Nordic countries European Journal of Clinical Pharmacology. 54:1998;119-124.
16. Kirss F., Tuimala R. The prevalence of climacteric complaints and the use of HRT in Estonia. Maturitas. 35(Suppl. 1):2000;75.
17. Lember M., Sarapuu H., Pikk A., Kalda R. Family planning and family doctors in Estonia. Scandinavian Journal of Public Health. 27:1999;235-236.
18. Lexchin J. Improving the appropriateness of physician prescribing. International Journal of Health Services. 28:1998;253-267.
19. Mosca L., Collins P., Herrington D., Mendelsohn M., Pasternak R., Robertson R., Schenk-Gustafsson K., Smith S., Taubert K., Wenger N. Hormone replacement therapy and cardiovascular disease - A statement for health care professionals from the American heart association. Circulation. 104:2001;499-503.
20. National Agency for Medicines and Social Institution (2001). Finnish Statistics on Medicines 2000. Helsinki.
21. Oxman A., Thomson M., Davis D., Haynes B. No magic bullets. A systematic review of 102 trials of interventions to improve professional practice Canadian Medical Association Journal. 153:1995;1423-1431.
22. Petitti D. Hormone replacement therapy for prevention. More evidence, more pessimism. Journal of the American Medical Association. 288:2002;99-101.
23. Smetnik V. A review of HRT epidemiology in Russia. European Menopause Journal. 3:1996;284-285.
24. Tekkel, M. (1999). Hormoon asendusravi postmenopausis. Eesti Arst, 1, 50-55.
25. Toiviainen H., Hemminki E. Finnish physicians' attitudes towards preconsultation information. Menopausal treatment practices as an example Patient Education and Counseling. 35:1998;101-109.
26. UNDP (2002). Human Development Report 2001. Available http://www.undp.org/hdr2001/back.pdf (accessed: 11.3.2002).
27. Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift. Journal of the American Medical Association. 283:2000;373-380.
28. WHO Collaborating Centre for Drug Statistics Methodology and Nordic Council on Medicines (1990). Guidelines for ATC classification. Oslo.
29. Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy post-menopausal women. Journal of the American Medical Association, 288, 321-333.